As neutrophil migration into inflammatory sites can be prevented by targeting CXCR1 and CXCR2 receptors, we recently tested whether blocking these chemokine receptors by an allosteric inhibitor (ladarixin, LDX) (16) was able to modify the development of type 1 diabetes. The gene discussed is CXCR1; the disease is type 1 diabetes mellitus.